Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CYTO
DateTimeSourceHeadlineSymbolCompany
28/05/202415:31GlobeNewswire Inc.Altamira Therapeutics Provides Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
23/05/202413:47GlobeNewswire Inc.Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalNASDAQ:CYTOAltamira Therapeutics Ltd
16/05/202421:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
01/05/202413:47GlobeNewswire Inc.Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationNASDAQ:CYTOAltamira Therapeutics Ltd
24/04/202413:47GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
10/04/202413:00GlobeNewswire Inc.Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
04/04/202413:45GlobeNewswire Inc.Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
25/03/202412:47GlobeNewswire Inc.Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesNASDAQ:CYTOAltamira Therapeutics Ltd
07/02/202413:47GlobeNewswire Inc.Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
24/01/202413:47GlobeNewswire Inc.Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentNASDAQ:CYTOAltamira Therapeutics Ltd
22/01/202422:02Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CYTOAltamira Therapeutics Ltd
22/01/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
19/01/202421:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
19/01/202421:40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CYTOAltamira Therapeutics Ltd
19/01/202421:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
08/01/202422:02Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:CYTOAltamira Therapeutics Ltd
08/01/202413:47GlobeNewswire Inc.Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitNASDAQ:CYTOAltamira Therapeutics Ltd
29/12/202313:47GlobeNewswire Inc.Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:CYTOAltamira Therapeutics Ltd
11/12/202313:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
11/12/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
11/12/202313:00GlobeNewswire Inc.Altamira Therapeutics Provides Investor and Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
08/12/202314:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
05/12/202317:54GlobeNewswire Inc.Altamira Therapeutics to Host Investor & Business Update Call on December 11thNASDAQ:CYTOAltamira Therapeutics Ltd
29/11/202315:20GlobeNewswire Inc.Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNASDAQ:CYTOAltamira Therapeutics Ltd
22/11/202321:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
21/11/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
17/11/202314:04GlobeNewswire Inc.Altamira Therapeutics Announces Partial Spin-Off of Bentrio® BusinessNASDAQ:CYTOAltamira Therapeutics Ltd
10/11/202313:47GlobeNewswire Inc.Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal BetahistineNASDAQ:CYTOAltamira Therapeutics Ltd
31/10/202320:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
04/10/202314:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CYTO